Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496120 | 0.95 | HRH4 (0.43) | HRH4TRPV1 | |
| SCHEMBL6487554 | 0.86 | PTGES (0.51) | CNR2HRH4FAAHTRPV1 | |
| SCHEMBL14824496 | 0.80 | FAAH (0.44) | FAAH | |
| SCHEMBL6492116 | 0.80 | LMNA (0.51) | CNR2 | |
| SCHEMBL6488071 | 0.80 | PTGES (0.57) | CNR2HRH4FAAH | |
| SCHEMBL6500082 | 0.79 | HTR6 (0.42) | HRH4 | |
| SCHEMBL6499476 | 0.77 | HRH4 (0.42) | HRH4TRPV1 | |
| SCHEMBL6488338 | 0.77 | PTGES (0.42) | HRH4TRPV1 | |
| SCHEMBL6488417 | 0.76 | FAAH (0.51) | CNR2HRH4FAAH | |
| SCHEMBL6487287 | 0.74 | LMNA (0.55) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867226-B2 | Serotonin 5-HT3 receptor partial activator | MEIJI SEIKA KAISHA, LTD. (JP) | 2005-03-15 | — | — | US | disclosed |
| US-6552057-B2 | In addition to 5-HT3 receptor antagonism, and inhibiting diarrhea without causing constipation as side effect; benzoxazole derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| EP-0806419-B1 | Benzoxazole derivatives as serotonin 5-HT3 receptor partial activator | MEIJI SEIKA KAISHA (JP) | 2003-04-02 | — | — | EP | disclosed |
| US-20030013730-A1 | Serotonin 5-HT3 receptor partial activator | MEIJI SEIKA KAISHA, LTD. | 2003-01-16 | — | — | US | disclosed |
| US-6333328-B1 | MIXING BENZOXAZOLE DERIVATIVE WITH CARRIER TO FORM ACTIVATOR COMPOUND | MEIJI SEIKA KAISHA, LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| US-6297246-B1 | BENZOXAZOLE DERIVATIVES; DOES NOT CAUSE CONSTIPATION AS A SIDE EFFECT. | MEIJI SEIKA KAISHA LTD. (JP) | 2001-10-02 | — | — | US | disclosed |
| US-20010016579-A1 | Serotonin 5-HT, receptor partial activator | LOTUS PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | US | disclosed |
| US-6037342-A | BENZOXAZOLE DERIVATIVES HAVING STRONG SEROTONIN 5-HT.SUB.3 RECEPTOR ANTAGONISM; TREATING FUNCTIONAL DISORDERS OF DIGESTIVE ORGANS | MEIJI SEIKA KAISHA, LTD (JP) | 2000-03-14 | — | — | US | disclosed |
| EP-0806419-A1 | Benzoxazole derivatives as serotonin 5-HT3 receptor partial activator | MEIJI SEIKA KAISHA LTD. (JP) | 1997-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016579-A1 | Serotonin 5-HT, receptor partial activator | HTR7, HTR1A, HTR3A | CNR2 57/4885HRH4 54/4885FAAH 205/4885 |
| US-20030013730-A1 | Serotonin 5-HT3 receptor partial activator | HTR7, HTR3A, HTR1A | CNR2 66/4885HRH4 55/4885FAAH 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.